Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Glaxosmithkline Plc ADR (GSK)

Glaxosmithkline Plc ADR (GSK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 111,392,648
  • Shares Outstanding, K 2,692,595
  • Annual Sales, $ 43,783 M
  • Annual Income, $ 7,382 M
  • 60-Month Beta 0.74
  • Price/Sales 2.53
  • Price/Cash Flow 10.62
  • Price/Book 3.69
Trade GSK with:

Options Overview Details

View History
  • Implied Volatility 26.09%
  • Historical Volatility 16.95%
  • IV Percentile 91%
  • IV Rank 32.09%
  • IV High 47.71% on 01/27/21
  • IV Low 15.88% on 08/27/21
  • Put/Call Vol Ratio 0.63
  • Today's Volume 2,290
  • Volume Avg (30-Day) 11,726
  • Put/Call OI Ratio 0.20
  • Today's Open Interest 127,321
  • Open Int (30-Day) 142,875

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/21
See More
  • Average Estimate 0.67
  • Number of Estimates 4
  • High Estimate 0.83
  • Low Estimate 0.58
  • Prior Year 0.62
  • Growth Rate Est. (year over year) +8.06%

Price Performance

See More
Period Period Low Period High Performance
1-Month
40.81 +1.37%
on 11/26/21
43.61 -5.14%
on 11/03/21
-1.22 (-2.86%)
since 11/01/21
3-Month
37.80 +9.44%
on 10/06/21
43.61 -5.14%
on 11/03/21
+0.26 (+0.63%)
since 09/01/21
52-Week
33.53 +23.38%
on 02/26/21
43.61 -5.14%
on 11/03/21
+3.85 (+10.26%)
since 12/01/20

Most Recent Stories

More News
AbbVie (ABBV) Files for Skyrizi to Treat Crohn's Disease in EU

AbbVie (ABBV) submits a regulatory application in the European Union, seeking approval for risankizumab (Skyrizi) for the treatment of Crohn's disease.

GSK : 41.37 (+0.61%)
ENDP : 5.27 (-5.89%)
ABBV : 115.91 (+0.55%)
ISEE : 14.12 (-3.42%)
AstraZeneca, Merck's Lynparza sNDA Gets FDA Priority Tag

FDA grants priority review to AstraZeneca (AZN) and Merck's (MRK) sNDA for Lynparza for BRCA-mutated HER2-negative high-risk early breast cancer.

AZN : 54.88 (+0.09%)
GSK : 41.37 (+0.61%)
MRK : 74.44 (-0.63%)
CLVS : 2.94 (-6.96%)
Merck's (MRK) Keytruda Gets Europe Nod for Two Carcinomas

Merck's (MRK) Keytruda, in combination with Eisai's Lenvima, gets approval for treating first-line renal cell carcinoma and recurrent endometrial carcinoma in Europe.

GSK : 41.37 (+0.61%)
PFE : 54.68 (+1.77%)
MRK : 74.44 (-0.63%)
SRPT : 82.19 (+1.71%)
Are These Medical Stocks Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest...

GSK : 41.37 (+0.61%)
HLUYY : 25.0000 (-0.02%)
3 Pharma Stocks Too Cheap to Ignore

As a new COVID-19 variant (omnicron) raises concerns worldwide, we think it could be wise to scoop up the shares of quality pharmaceutical stocks GlaxoSmithKline (GSK), Teva Pharmaceutical (TEVA), and...

GSK : 41.37 (+0.61%)
TEVA : 8.18 (-0.85%)
EGRX : 47.86 (+0.38%)
Glaxo (GSK) Upgraded to Strong Buy: Here's Why

Glaxo (GSK) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

GSK : 41.37 (+0.61%)
Novavax (NVAX) Stock Up YTD on COVID-19 Vaccine Potential

Novavax (NVAX) is likely to generate huge revenues as the company has started filing approvals for emergency use of its COVID-19 vaccine in multiple nations.

GSK : 41.37 (+0.61%)
NVAX : 192.65 (-7.66%)
DTIL : 8.62 (-4.86%)
ISEE : 14.12 (-3.42%)
Should You Buy the Dip in Tilray?

Canada-based cannabis producer Tilray’s (TLRY) acquisition strategy could drive its long-term growth. However, the company’s shares have fallen in price significantly over the past six months. Uncertainty...

TLRY : 9.27 (-8.40%)
JNJ : 158.08 (+1.38%)
MRK : 74.44 (-0.63%)
GSK : 41.37 (+0.61%)
Gilead Sciences (GILD) Stock Gains 20% YTD: What Lies Ahead?

Gilead's (GILD) performance in the year has been pretty good on contribution from Veklury. The company is now focusing on its oncology business as the virology business faces challenges.

GSK : 41.37 (+0.61%)
GILD : 68.93 (unch)
SRPT : 82.19 (+1.71%)
RCUS : 43.13 (-1.53%)
Is GlaxoSmithKline (GSK) Outperforming Other Medical Stocks This Year?

Here is how GlaxoSmithKline (GSK) and Omnicell (OMCL) have performed compared to their sector so far this year.

GSK : 41.37 (+0.61%)
OMCL : 176.39 (-0.34%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

GlaxoSmithKline is one of the world's leading research based pharmaceutical and healthcare companies and is committed to improving the quality of human life by enabling people to do more, feel better and live longer. They also have leadership in four major therapeutic areas: anti-infectives, central...

See More

Key Turning Points

3rd Resistance Point 42.11
2nd Resistance Point 41.93
1st Resistance Point 41.65
Last Price 41.37
1st Support Level 41.18
2nd Support Level 41.00
3rd Support Level 40.72

See More

52-Week High 43.61
Last Price 41.37
Fibonacci 61.8% 39.76
Fibonacci 50% 38.57
Fibonacci 38.2% 37.38
52-Week Low 33.53

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar